Phaseline

Targets › TGFB2

TGFB2 (Transforming growth factor beta-2 proprotein): drug programs, companies and trials

4 programs from 3 companies in 28 trials: 13 Phase 2, 7 Phase 3, 7 Phase 1, 1 Phase 4; Oncology, Hematology, Ophthalmology; next expected readout Dec 2026.

[Transforming growth factor beta-2 proprotein]: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively..; FUNCTION: [Latency-associated peptide]: Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By…. (UniProt, P61812)

Open in Phaseline: the race on TGFB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbLuspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 4Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance …Jul 2027
Bristol-Myers SquibbLuspatercept (ACE-536)
Transforming growth factor beta inhibitor
TGFB1, TGFB2, TGFB3Phase 3Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-ThalassemiaSep 2027
National Cancer Institute (NCI)Bintrafusp Alfa (M7824)
Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent
CD274, TGFB1, TGFB2, TGFB3Phase 2Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial CancerDec 2026
OncotelicTrabedersen (OT-101)
Transforming growth factor beta-2 mRNA antisense inhibitor
TGFB2Phase 2Pancreatic Ductal Adenocarcinoma; Myopia, Progressive; Non-small Cell Lung CancerJun 2027

Conditions

Myelodysplastic Syndromes (8) Anemia (3) Pancreatic Ductal Adenocarcinoma (1) Myopia, Progressive (1) Non-small Cell Lung Cancer (1) Thymic Epithelial Tumor (1) Cancer Of Prostate (1) Kaposi Sarcoma (1) Urothelial Cancer (1) Beta-thalassemia (1) CCUS Clonal Cytopenia of Undetermined Significance (1) Transfusion-dependent β-thalassemia Patients (1)

Modalities

small molecule (2), antibody (2)

Companies

Bristol-Myers Squibb (2) Oncotelic (1) National Cancer Institute (NCI) (1)

Related targets

TGFB1 (3) TGFB3 (3) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.